^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:...as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:...in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.
    Secondary therapy:
    5-fluorouracil
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

    Published date:
    12/15/2022
    Excerpt:
    Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers....Recommendation 3.1….Pembrolizumab or nivolumab should be offered to patients with platinum-refractory recurrent or metastatic HNSCC, regardless of CPS status
    DOI:
    10.1200/JCO.22.02328
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    11/01/2020
    Excerpt:
    ChT plus pembrolizumab is recommended when rapid tumour shrinkage is needed.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1016/j.annonc.2020.07.011
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    A summary of management strategies for recurrent and/or metastatic SCCHN...Pretreated with platinum based ChT within the last 6 months and immunotherapy naïve...Standard...pembrolizumab
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO 2018
    Title:

    KEYNOTE-412: Phase 3 Study of Pembrolizumab Plus Chemoradiation vs Chemoradiation Alone for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

    Published date:
    10/01/2018
    Excerpt:
    KEYNOTE-412 is a phase 3, randomized, placebo-controlled, double-blind trial to determine efficacy and safety of pembrolizumab plus CRT and as maintenance therapy vs placebo plus CRT in LA-HNSCC...Patients will be randomly assigned (1:1) to receive pembrolizumab 200 mg every 3 weeks plus cisplatin-based CRT or placebo plus cisplatin-based CRT...Primary end point is event-free survival and secondary end points are overall survival, safety, and patient-reported outcomes.
    Secondary therapy:
    cisplatin
    DOI:
    https://doi.org/10.1093/annonc/mdy287.078
    Trial ID:
    KEYNOTE-412